Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

Although pTau217 and pTau181 were highly correlated at baseline ( r = 0.774, p < 0.0001), the treatment effect of HMTM 16 mg/day on pTau181 was directionally consistent but did not reach statistical significance ( p = 0·1699). 3.5.

also in 111,027 other papers

This was demonstrated by highly significant differences on cognitive and functional outcomes in comparisons with meta-analytic controls based on true placebo data from trials in comparable populations in which participants received inactive infusions.

also in 132,142 other papers